Sermion

Nicergoline

Acute or chronic, peripheral & cerebral vasculo-metabolic disorders w/ signs & symptoms of cerebral insufficiency or dementia eg, impaired memory & conc, dizziness, depressed mood, impaired self-care & sleep-walking cycle, disorientation in time & place, tinnitus, blurred vision, performance insufficiency, headache & fatigue. Obliterative arteriopathies of the limbs: Raynaud's syndrome & all syndromes due to altered peripheral flow. Headache in geriatric arteriosclerotic patients. Adjuvant to therapy of arterial HTN & parenterally, of hypertensive crises. Signs & symptoms of mental deterioration eg, cognitive, affective, behavioural & somatic disturbances associated w/ cerebral deterioration (chronic cerebrovascular insufficiency &/or senile & pre-senile dementia, Parkinson's disease); decreased vigilance, apathy, interpersonal relationships, asthenia, anorexia. Co-adjuvant in the rehabilitative treatment of hemiplegic patients w/ ictus sequelae.

10-mg tab 10 mg tid. 30-mg tab 60 mg/day in 2 administrations. Take at regular intervals.

May be taken with or without food: Preferably taken before meals.

Hypersensitivity.

Pulmonary, cardiac, cardiac valvular & retroperitoneal fibrosis, symptoms of ergotism (eg, nausea, vomiting, diarrhea, abdominal pain & peripheral vasoconstriction). Patients w/ hyperuricemia or history of gout; under treatment w/ drugs that might interfere w/ metabolism & excretion of uric acid. Pregnancy.

Reduction in serum cholesterol & triglycerides & increase in uric acid in some cases. Hypotension, dizziness, very slight gastric distress, flushing, sleepiness & insomnia may occur very rarely.

May potentiate action of antihypertensives.

Neurodegenerative Disease Drugs / Peripheral Vasodilators & Cerebral Activators / Antivertigo Drugs

C04AE02 - nicergoline ; Belongs to the class of ergot alkaloids. Used as peripheral vasodilators.

D